| 1 | An Overview of Real-World Data Infrastructure for Cancer Research | 1.6 | 10 | Citations (PDF) |
| 2 | Dosimetric impact of sparing base of heart on organ at risk doses during lung radiotherapy | 2.0 | 6 | Citations (PDF) |
| 3 | An international and multidisciplinary EORTC survey on resectability of stage III non-small cell lung cancer | 2.6 | 46 | Citations (PDF) |
| 4 | Association of radiation-induced normal tissue toxicity with a high genetic risk for rheumatoid arthritis | 4.6 | 1 | Citations (PDF) |
| 5 | The Effect of the Concurrent Use of Angiotensin-Converting Enzyme Inhibitors or Receptor Blockers on Toxicity and Outcomes in Patients Treated with Radiotherapy: A Systematic Review and Meta-Analysis | 4.2 | 3 | Citations (PDF) |
| 6 | 171 Impact of Dose to a Novel Cardiac Avoidance Area on Cardiac Mortality in 3,459 Lung Cancer Patients Receiving Curative Radiotherapy | 2.6 | 0 | Citations (PDF) |
| 7 | Mastering CT-based radiomic research in lung cancer: a practical guide from study design to critical appraisal | 2.4 | 1 | Citations (PDF) |
| 8 | Response to “Letter to Editor-in-Chief” and “Redefining Resectability: Bridging Perspectives in Stage III NSCLC Management” | 2.6 | 1 | Citations (PDF) |
| 9 | Diagnosis and treatment of radiation induced pneumonitis in patients with lung cancer: An ESTRO clinical practice guideline | 2.0 | 36 | Citations (PDF) |
| 10 | Physician specialty shapes hypothetical self-treatment choices for locally advanced non−small cell lung cancer: Is the “best” option subjective? | 1.2 | 0 | Citations (PDF) |
| 11 | Emerging Role of Targeted Therapies Combined With Radiotherapy in Inoperable Stages I to III NSCLC: A Review From the IASLC ART Subcommittee | 2.1 | 5 | Citations (PDF) |
| 12 | 2889 PRIMALung (EORTC-1901) preliminary data: PRophylactic cerebral Irradiation (PCI) or active brain MRI surveillance in SCLC patients | 2.0 | 0 | Citations (PDF) |
| 13 | 4424 Dosimetric evaluation of two cardiac substructure segmentation approaches: walls versus chambers | 2.0 | 0 | Citations (PDF) |
| 14 | Consolidation thoracic radiotherapy after chemoimmunotherapy in ES-SCLC: A multicentric retrospective analysis | 4.9 | 8 | Citations (PDF) |
| 15 | Surgery or radiotherapy for early-stage cancer study (SORT) target trial protocol: stereotactic ablative radiotherapy (SABR) with curative intent versus surgical resection for early-stage non-small cell lung cancer (NSCLC) | 1.9 | 3 | Citations (PDF) |
| 16 | An introduction to pragmatic trials in lung cancer research: A multi-faceted approach | 2.6 | 2 | Citations (PDF) |
| 17 | Integrating Electronic Patient-Reported Outcome Measures (ePROMs) into Personalised Follow-up for Patients after Radiotherapy. A Feasibility Study | 2.1 | 1 | Citations (PDF) |
| 18 | Targeted treatment for unresectable EGFR mutation-positive stage III non-small cell lung cancer: Emerging evidence and future perspectives | 2.6 | 15 | Citations (PDF) |
| 19 | Exploring the Advantages and Challenges of MR-Guided Radiotherapy in Non–Small-Cell Lung Cancer: Who are the Optimal Candidates? | 2.7 | 7 | Citations (PDF) |
| 20 | Oral anticoagulant prescribing among patients with cancer and atrial fibrillation in England, 2009–2019 | 4.0 | 3 | Citations (PDF) |
| 21 | Response to Letter to the Editor From Shaorong Yu and Jifeng Feng | 2.1 | 2 | Citations (PDF) |
| 22 | Long-Term Outcomes After Concurrent Once- or Twice-Daily Chemoradiation in Limited-Stage Small Cell Lung Cancer: A Brief Report From the CONVERT Trial | 1.5 | 26 | Citations (PDF) |
| 23 | A study demonstrating users’ preference for the adapted-REQUITE patient-reported outcome questionnaire over PRO-CTCAE® in patients with lung cancer | 2.6 | 6 | Citations (PDF) |
| 24 | Treatment Response Biomarkers: Working Toward Personalized Radiotherapy for Lung Cancer | 2.1 | 14 | Citations (PDF) |
| 25 | Patient-reported outcomes after personalised dose-escalation for stage II-III non-small-cell lung cancer patients: Results from the randomised ARTFORCE PET-Boost trial | 2.0 | 1 | Citations (PDF) |
| 26 | Optimal management of radiation pneumonitis: Findings of an international Delphi consensus study | 2.6 | 18 | Citations (PDF) |
| 27 | Performance of CHA2DS2-VASc and HAS-BLED in predicting stroke and bleeding in atrial fibrillation and cancer | 2.5 | 9 | Citations (PDF) |
| 28 | The Development and Feasibility of a Novel Electronic Patient-Reported Outcome Measures (Eproms) Questionnaire in patients with penile cancer | 2.3 | 4 | Citations (PDF) |
| 29 | Measuring repeatability of dynamic contrast-enhanced MRI biomarkers improves evaluation of biological response to radiotherapy in lung cancer | 3.6 | 7 | Citations (PDF) |
| 30 | Simultaneous implementation of unrelated tumour sites on the MR Linac: A review of the commissioning process from a radiographer perspective and lessons learned | 0.4 | 0 | Citations (PDF) |
| 31 | Comorbidity in patients with cancer treated at The Christie | 5.5 | 10 | Citations (PDF) |
| 32 | A Response to the Letter to the Editor: The Role of Personalization and Standardization in Stereotactic Body Radiation Therapy | 2.1 | 1 | Citations (PDF) |
| 33 | Non-small-cell lung cancer | 46.9 | 431 | Citations (PDF) |
| 34 | A Response to the Letter to the Editor: “Comment on Stereotactic Body Radiotherapy for Centrally Located Inoperable Early Stage NSCLC: EORTC 22113-08113 LungTech Phase II Trial Results” | 2.1 | 2 | Citations (PDF) |
| 35 | Prise en charge des cancers bronchiques à petites cellules de stade localisé i actualisation | 0.0 | 0 | Citations (PDF) |
| 36 | PRIMALung (EORTC-1901): PRophylactic cerebral irradiation (PCI) or active brain MAgnetic resonance imaging (MRI) surveillance in small-cell lung cancer (SCLC) patients | 2.6 | 13 | Citations (PDF) |
| 37 | Challenges and opportunities for real-world evidence in clinical oncology—a view from the UK: proceedings of a national workshop | 0.5 | 3 | Citations (PDF) |
| 38 | European Respiratory Society guideline on various aspects of quality in lung cancer care | 8.7 | 27 | Citations (PDF) |
| 39 | In Reply to Chowdhry et al. | 1.5 | 1 | Citations (PDF) |
| 40 | To the Editor | 2.1 | 0 | Citations (PDF) |
| 41 | Association between radiotherapy protocol variations and outcome in the CONVERT trial | 0.9 | 1 | Citations (PDF) |
| 42 | Demystifying the Results of RTOG 0617: Identification of Dose Sensitive Cardiac Subregions Associated With Overall Survival | 2.1 | 69 | Citations (PDF) |
| 43 | PRIMALung (EORTC-1901-LCG): prophylactic cerebral irradiation or active brain magnetic resonance imaging surveillance in small-cell lung cancer patients | 2.6 | 0 | Citations (PDF) |
| 44 | Implementing heart-sparing radiotherapy for lung cancer | 2.6 | 1 | Citations (PDF) |
| 45 | Patient and clinician-reported experiences of using electronic patient reported outcome measures (ePROMs) as part of routine cancer care | 2.6 | 28 | Citations (PDF) |
| 46 | Reply to the Letter by Ma et al | 2.1 | 0 | Citations (PDF) |
| 47 | Predicting cancer relapse following lung stereotactic radiotherapy: an external validation study using real-world evidence | 2.6 | 3 | Citations (PDF) |
| 48 | PO-2117 CTV-free lung planning: Can we reduce toxicity whilst maintaining local control? | 2.0 | 0 | Citations (PDF) |
| 49 | Common Cancer Types and Risk of Stroke and Bleeding in Patients With Nonvalvular Atrial Fibrillation: A Population‐Based Study in England | 4.0 | 19 | Citations (PDF) |
| 50 | Fixing the Leaky Pipe: How to Improve the Uptake of Patient-Reported Outcomes–Based Prognostic and Predictive Models in Cancer Clinical Practice | 2.0 | 11 | Citations (PDF) |
| 51 | EP08.01-03 Lymphocyte Count Pre-immunotherapy Predicts Progression-Free Survival in Stage III NSCLC Treated with Chemoradiotherapy and Immunotherapy | 2.1 | 0 | Citations (PDF) |
| 52 | A novel use for routine CBCT imaging during radiotherapy to detect COVID-19 | 2.2 | 5 | Citations (PDF) |
| 53 | Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆ | 9.9 | 219 | Citations (PDF) |
| 54 | Targeting PARP for Chemoradiosensitization: Opportunities, Challenges, and the Road Ahead | 1.5 | 4 | Citations (PDF) |
| 55 | Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART, IFCT 0503): an open-label, randomised, phase 3 trial | 27.4 | 251 | Citations (PDF) |
| 56 | Initial Clinical Experience of Routine Electronic Patient-Reported Outcome Measures at the Christie NHS Foundation Trust | 1.6 | 3 | Citations (PDF) |
| 57 | Effect of systemic inflammation biomarkers on overall survival after lung cancer radiotherapy: a single-center large-cohort study | 1.8 | 20 | Citations (PDF) |
| 58 | Evaluation of Prognostic and Predictive Models in the Oncology Clinic | 1.6 | 28 | Citations (PDF) |
| 59 | Postoperative Radiation Therapy Should Not Be Used for the Therapy of Stage III-N2 NSCLC | 2.1 | 13 | Citations (PDF) |
| 60 | Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial | 2.6 | 25 | Citations (PDF) |
| 61 | Excess years of life lost to COVID-19 and other causes of death by sex, neighbourhood deprivation, and region in England and Wales during 2020: A registry-based study | 8.0 | 43 | Citations (PDF) |
| 62 | Radial Data Mining to Identify Density–Dose Interactions That Predict Distant Failure Following SABR | 2.6 | 5 | Citations (PDF) |
| 63 | Overview of health-related quality of life and toxicity of non-small cell lung cancer patients receiving curative-intent radiotherapy in a real-life setting (the REQUITE study) | 2.6 | 12 | Citations (PDF) |
| 64 | Understanding the Differences Between Bayesian and Frequentist Statistics | 1.5 | 88 | Citations (PDF) |
| 65 | Rationale and Design of the Phase 3 KEYLYNK-013 Study of Pembrolizumab With Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Limited-Stage Small-Cell Lung Cancer | 2.8 | 14 | Citations (PDF) |
| 66 | Exposure of the heart in lung cancer radiation therapy: A systematic review of heart doses published during 2013 to 2020 | 2.0 | 27 | Citations (PDF) |
| 67 | Causal relation between heart irradiation and survival of lung cancer patients after radiotherapy | 2.0 | 15 | Citations (PDF) |
| 68 | Exercise in lung Cancer, the healthcare providers opinion (E.C.H.O.): Results of the EORTC lung cancer Group (LCG) survey | 2.6 | 21 | Citations (PDF) |
| 69 | Unaccounted Confounders Limit the Ability to Draw Conclusions From Big Data Analysis Comparing Radiotherapy Fractionation Regimens in NSCLC | 2.1 | 0 | Citations (PDF) |
| 70 | Avoiding Toxicity With Lung Radiation Therapy: An IASLC Perspective | 2.1 | 26 | Citations (PDF) |
| 71 | Impact of Introducing Intensity Modulated Radiotherapy on Curative Intent Radiotherapy and Survival for Lung Cancer | 2.6 | 12 | Citations (PDF) |
| 72 | Role of Real-World Data in Assessing Cardiac Toxicity After Lung Cancer Radiotherapy | 2.6 | 15 | Citations (PDF) |
| 73 | Bayesian methods provide a practical real-world evidence framework for evaluating the impact of changes in radiotherapy | 2.0 | 1 | Citations (PDF) |
| 74 | Prise en charge des formes oligométastatiques : l’avis de l’oncologue thoracique | 0.0 | 0 | Citations (PDF) |
| 75 | Prognostic value of patient-reported outcome measures (PROMs) in adults with non-small cell Lung Cancer: a scoping review | 2.9 | 15 | Citations (PDF) |
| 76 | Heart dose and cardiac comorbidities influence death with a cardiac cause following hypofractionated radiotherapy for lung cancer | 2.6 | 14 | Citations (PDF) |
| 77 | Introducing magnetic resonance imaging into the lung cancer radiotherapy workflow – An assessment of patient experience | 2.2 | 11 | Citations (PDF) |
| 78 | Role of radiotherapy in the management of brain metastases of NSCLC – Decision criteria in clinical routine | 2.0 | 16 | Citations (PDF) |
| 79 | Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC) | 2.6 | 52 | Citations (PDF) |
| 80 | Isotoxic Intensity Modulated Radiation Therapy in Stage III Non-Small Cell Lung Cancer: A Feasibility Study | 1.5 | 22 | Citations (PDF) |
| 81 | Automated gross tumor volume contour generation for large‐scale analysis of early‐stage lung cancer patients planned with 4D‐CT | 3.1 | 6 | Citations (PDF) |
| 82 | Safety of G-CSF with concurrent chemo-radiotherapy in limited-stage small cell lung cancer - Secondary analysis of the randomised phase 3 CONVERT trial | 2.6 | 17 | Citations (PDF) |
| 83 | Thoracic radiotherapy in small cell lung cancer—a narrative review | 2.0 | 22 | Citations (PDF) |
| 84 | EPAC-lung: European pooled analysis of the prognostic value of circulating tumour cells in small cell lung cancer | 2.0 | 11 | Citations (PDF) |
| 85 | Patient-Reported Outcomes with Durvalumab by PD-L1 Expression and Prior Chemoradiotherapy-Related Variables in Unresectable Stage III Non-Small-Cell Lung Cancer | 2.3 | 2 | Citations (PDF) |
| 86 | Optimising use of 4D-CT phase information for radiomics analysis in lung cancer patients treated with stereotactic body radiotherapy | 3.1 | 14 | Citations (PDF) |
| 87 | Phase I trial of the MEK inhibitor selumetinib in combination with thoracic radiotherapy in non-small cell lung cancer | 0.9 | 4 | Citations (PDF) |
| 88 | MRI and CBCT for lymph node identification and registration in patients with NSCLC undergoing radical radiotherapy | 2.0 | 11 | Citations (PDF) |
| 89 | Development of a method for generating SNP interaction-aware polygenic risk scores for radiotherapy toxicity | 2.0 | 26 | Citations (PDF) |
| 90 | Routine electronic patient reported outcomes measures (ePROMs) for patients with lung cancer | 2.6 | 1 | Citations (PDF) |
| 91 | Stereotactic Radiation for Lung Cancer: A Practical Approach to Challenging Scenarios | 2.1 | 34 | Citations (PDF) |
| 92 | Patterns of Care, Tolerability, and Safety of the First Cohort of Patients Treated on a Novel High-Field MR-Linac Within the MOMENTUM Study: Initial Results From a Prospective Multi-Institutional Registry | 1.5 | 56 | Citations (PDF) |
| 93 | Outcomes of curative-intent radiotherapy in non-small cell lung cancer (NSCLC) patients with chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD) | 2.0 | 12 | Citations (PDF) |
| 94 | OC-0534 Image review for COVID-19 on CBCT vs MIP’s | 2.0 | 0 | Citations (PDF) |
| 95 | Excess deaths from COVID-19 and other causes by region, neighbourhood deprivation level and place of death during the first 30 weeks of the pandemic in England and Wales: A retrospective registry study | 6.9 | 52 | Citations (PDF) |
| 96 | Role of Postoperative Radiotherapy in the Management for Resected NSCLC – Decision Criteria in Clinical Routine Pre- and Post-LungART | 2.8 | 17 | Citations (PDF) |
| 97 | PD-0776 A Bayesian approach to evaluate the impact of change in IGRT protocol using real world data | 2.0 | 0 | Citations (PDF) |
| 98 | Small-cell lung cancer | 46.9 | 1,388 | Citations (PDF) |
| 99 | Cancers bronchiques de stade III : rôle de l’onco-radiothérapeute | 0.0 | 0 | Citations (PDF) |
| 100 | Prise en charge des cancers bronchiques non à petites cellules oligométastatiques | 0.0 | 0 | Citations (PDF) |
| 101 | Sites of First Progression in the Randomized PET-Boost Trial for Patients With Locally Advanced NSCLC | 1.5 | 1 | Citations (PDF) |
| 102 | Learning healthcare systems and rapid learning in radiation oncology: Where are we and where are we going? | 2.0 | 19 | Citations (PDF) |
| 103 | Prophylactic cranial irradiation (PCI), hippocampal avoidance (HA) whole brain radiotherapy (WBRT) and stereotactic radiosurgery (SRS) in small cell lung cancer (SCLC): Where do we stand? | 2.6 | 26 | Citations (PDF) |
| 104 | Profiling of Circulating Free DNA Using Targeted and Genome-wide Sequencing in Patients with SCLC | 2.1 | 72 | Citations (PDF) |
| 105 | Multifactorial risk factors for mortality after chemotherapy and radiotherapy for non-small cell lung cancer | 2.0 | 38 | Citations (PDF) |
| 106 | Is tumour sphericity an important prognostic factor in patients with lung cancer? | 2.0 | 31 | Citations (PDF) |
| 107 | Recommendation for supportive care in patients receiving concurrent chemotherapy and radiotherapy for lung cancer | 9.9 | 97 | Citations (PDF) |
| 108 | Distributed learning on 20 000+ lung cancer patients – The Personal Health Train | 2.0 | 135 | Citations (PDF) |
| 109 | The role of postoperative thoracic radiotherapy and prophylactic cranial irradiation in early stage small cell lung cancer: Patient selection among ESTRO experts | 2.0 | 16 | Citations (PDF) |
| 110 | The impact of baseline shifts towards the heart after image guidance on survival in lung SABR patients | 2.0 | 17 | Citations (PDF) |
| 111 | CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer | 0.9 | 18 | Citations (PDF) |
| 112 | Predictive value of vascular calcification identified in 4D planning CT of lung cancer patients treated with stereotactic body radiation therapy | 1.6 | 5 | Citations (PDF) |
| 113 | The MOMENTUM Study: An International Registry for the Evidence-Based Introduction of MR-Guided Adaptive Therapy | 2.6 | 143 | Citations (PDF) |
| 114 | Reliability and prognostic value of radiomic features are highly dependent on choice of feature extraction platform | 3.6 | 184 | Citations (PDF) |
| 115 | Impact of small residual setup errors after image guidance on heart dose and survival in non-small cell lung cancer treated with curative-intent radiotherapy | 2.0 | 15 | Citations (PDF) |
| 116 | Novel Methodology to Investigate the Effect of Radiation Dose to Heart Substructures on Overall Survival | 1.5 | 100 | Citations (PDF) |
| 117 | Radiomics as a personalized medicine tool in lung cancer: Separating the hope from the hype | 2.6 | 103 | Citations (PDF) |
| 118 | Practice Recommendations for Lung Cancer Radiotherapy During the COVID-19 Pandemic: An ESTRO-ASTRO Consensus Statement | 1.5 | 44 | Citations (PDF) |
| 119 | Radiotherapy-Related Lymphopenia Affects Overall Survival in Patients With Lung Cancer | 2.1 | 164 | Citations (PDF) |
| 120 | ESTRO ACROP guidelines for target volume definition in the thoracic radiation treatment of small cell lung cancer | 2.0 | 47 | Citations (PDF) |
| 121 | Protecting the Heart: A Practical Approach to Account for the Full Extent of Heart Motion in Radiation Therapy Planning | 1.5 | 13 | Citations (PDF) |
| 122 | SABRTooth: a randomised controlled feasibility study of stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage I nonsmall cell lung cancer considered to be at higher risk of complications from surgical resection | 8.7 | 49 | Citations (PDF) |
| 123 | Radiation Therapy for Small Cell Lung Cancer: An ASTRO Clinical Practice Guideline | 2.7 | 181 | Citations (PDF) |
| 124 | Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement | 2.0 | 193 | Citations (PDF) |
| 125 | Treatment of brain metastases in small cell lung cancer: Decision-making amongst a multidisciplinary panel of European experts | 2.0 | 15 | Citations (PDF) |
| 126 | Making Checkpoint Inhibitors Part of Treatment of Patients With Locally Advanced Lung Cancers: The Time Is Now | 4.4 | 9 | Citations (PDF) |
| 127 | Once daily versus twice-daily radiotherapy in the management of limited disease small cell lung cancer – Decision criteria in routine practise | 2.0 | 16 | Citations (PDF) |
| 128 | OC-0096: Peritumoural density as a biomarker of distant failure in NSCLC patients treated with SABR | 2.0 | 1 | Citations (PDF) |
| 129 | ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma | 1.4 | 83 | Citations (PDF) |
| 130 | ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma | 8.7 | 246 | Citations (PDF) |
| 131 | SP-0003 State of the art in definitive treatment of locally advanced NSCLC | 2.0 | 0 | Citations (PDF) |
| 132 | Inter-observer variability in target delineation increases during adaptive treatment of head-and-neck and lung cancer | 1.8 | 34 | Citations (PDF) |
| 133 | OC-0404 Dose to vascular calcifications is predictive for overall survival in lung cancer patients | 2.0 | 0 | Citations (PDF) |
| 134 | PV-0579 The impact of intra-thoracic anatomical changes on the delivery of lung SABR | 2.0 | 1 | Citations (PDF) |
| 135 | EP-1367 Target volumes in adaptive treatment of NSCLC show large discrepancies among experts | 2.0 | 0 | Citations (PDF) |
| 136 | EP-2064 A novel method for GTV generation for large-scale analysis of lung cancer patients planned with 4DCT | 2.0 | 0 | Citations (PDF) |
| 137 | Patterns of Disease Progression with Durvalumab in Stage III Non-small Cell Lung Cancer (PACIFIC) | 1.5 | 61 | Citations (PDF) |
| 138 | Definition of Synchronous Oligometastatic Non–Small Cell Lung Cancer—A Consensus Report | 2.1 | 282 | Citations (PDF) |
| 139 | Recent developments in limited stage small cell lung cancer | 2.0 | 27 | Citations (PDF) |
| 140 | EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic disease | 4.9 | 47 | Citations (PDF) |
| 141 | OC-0632 Radiotherapy-related lymphopenia affects overall survival in patients with lung cancer | 2.0 | 1 | Citations (PDF) |
| 142 | PO-1115 The UK lung SABR survey on behalf of the Advanced Radiotherapy Technologies Network | 2.0 | 0 | Citations (PDF) |
| 143 | EP-1986 Comparison of automatic OAR contour propagation from CT to MR lung images | 2.0 | 0 | Citations (PDF) |
| 144 | Curative Radiotherapy for Non-small Cell Lung Cancer: Practice Changing and Changing Practice? | 1.6 | 4 | Citations (PDF) |
| 145 | OC-0084 Baseline shifts towards the heart after IGRT are linked to overall survival in lung SABR patients | 2.0 | 1 | Citations (PDF) |
| 146 | Current management of limited-stage SCLC and CONVERT trial impact: Results of the EORTC Lung Cancer Group survey | 2.6 | 27 | Citations (PDF) |
| 147 | Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts | 2.0 | 26 | Citations (PDF) |
| 148 | OC-0062 Development & validation of prognostic and predictive models in limited-stage small-cell lung cancer | 2.0 | 0 | Citations (PDF) |
| 149 | Author's Reply to the: Letter to the Editor | 2.1 | 0 | Citations (PDF) |
| 150 | OC-0065 Cardiac dose and survival in lung cancer: which cardiac sub-structures matters most? | 2.0 | 0 | Citations (PDF) |
| 151 | REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer | 2.0 | 87 | Citations (PDF) |
| 152 | 18F-Fludeoxyglucose PET/CT in SCLC: Analysis of the CONVERT Randomized Controlled Trial | 2.1 | 43 | Citations (PDF) |
| 153 | Oxygen-enhanced MRI Is Feasible, Repeatable, and Detects Radiotherapy-induced Change in Hypoxia in Xenograft Models and in Patients with Non–small Cell Lung Cancer | 6.8 | 68 | Citations (PDF) |
| 154 | Quantitative evaluation of 4D Cone beam CT scans with reduced scan time in lung cancer patients | 2.0 | 19 | Citations (PDF) |
| 155 | Influence of tumour laterality on patient survival in non-small cell lung cancer after radiotherapy | 2.0 | 19 | Citations (PDF) |
| 156 | Prognostic value of circulating tumour cells in limited-stage small-cell lung cancer: analysis of the concurrent once-daily versus twice-daily radiotherapy (CONVERT) randomised controlled trial | 9.9 | 72 | Citations (PDF) |
| 157 | Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts | 2.0 | 16 | Citations (PDF) |
| 158 | Post-treatment lymphocytopaenia, integral body dose and overall survival in lung cancer patients treated with radical radiotherapy | 2.0 | 53 | Citations (PDF) |
| 159 | Accelerated, Dose escalated, Sequential Chemoradiotherapy in Non-small-cell lung cancer (ADSCaN): a protocol for a randomised phase II study | 1.9 | 12 | Citations (PDF) |
| 160 | Cancers bronchiques de stade III: rôle de l’onco-radiothérapeute | 0.0 | 0 | Citations (PDF) |
| 161 | Compliance and Outcome of Elderly Patients Treated in the Concurrent Once-Daily Versus Twice-Daily Radiotherapy (CONVERT) Trial | 2.1 | 48 | Citations (PDF) |
| 162 | The acute and late toxicity results of a randomized phase II dose-escalation trial in non-small cell lung cancer (PET-boost trial) | 2.0 | 76 | Citations (PDF) |
| 163 | Association of Chemoradiotherapy With Outcomes Among Patients With Stage I to II vs Stage III Small Cell Lung Cancer | 14.3 | 66 | Citations (PDF) |
| 164 | Diversity of brain metastases screening and management in non-small cell lung cancer in Europe: Results of the European Organisation for Research and Treatment of Cancer Lung Cancer Group survey | 4.9 | 80 | Citations (PDF) |
| 165 | British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma | 5.6 | 194 | Citations (PDF) |
| 166 | Current Practice of Whole Brain Radiotherapy in Metastatic Non-small Cell Lung Cancer | 1.6 | 1 | Citations (PDF) |
| 167 | Is heterogeneity in stage 3 non-small cell lung cancer obscuring the potential benefits of dose-escalated concurrent chemo-radiotherapy in clinical trials? | 2.6 | 13 | Citations (PDF) |
| 168 | A method to combine target volume data from 3D and 4D planned thoracic radiotherapy patient cohorts for machine learning applications | 2.0 | 13 | Citations (PDF) |
| 169 | Benefit of using motion compensated reconstructions for reducing inter-observer and intra-observer contouring variation for organs at risk in lung cancer patients | 2.0 | 9 | Citations (PDF) |
| 170 | Radiotherapy and anti-PD-1/PD-L1 combinations in lung cancer: building better translational research platforms | 9.9 | 133 | Citations (PDF) |
| 171 | ESTRO ACROP guidelines for target volume definition in the treatment of locally advanced non-small cell lung cancer | 2.0 | 194 | Citations (PDF) |
| 172 | Response to a Request for Clarification Regarding the Advanced Radiotherapy Technologies Network (ART-NET) | 1.6 | 0 | Citations (PDF) |
| 173 | Targeting Hypoxia to Improve Non–Small Cell Lung Cancer Outcome | 4.6 | 222 | Citations (PDF) |
| 174 | A prediction model for early death in non-small cell lung cancer patients following curative-intent chemoradiotherapy | 1.8 | 51 | Citations (PDF) |
| 175 | Cell Death, Inflammation, Tumor Burden, and Proliferation Blood Biomarkers Predict Lung Cancer Radiotherapy Response and Correlate With Tumor Volume and Proliferation Imaging | 2.8 | 16 | Citations (PDF) |
| 176 | Results from a clinical trial evaluating the efficacy of real-time body surface visual feedback in reducing patient motion during lung cancer radiotherapy | 1.8 | 7 | Citations (PDF) |
| 177 | [P176] Evaluating automatic contour propagation for estimating tumour shrinkage in small-cell lung cancer patients treated with chemo-radiotherapy | 1.6 | 0 | Citations (PDF) |
| 178 | Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC | 34.5 | 2,673 | Citations (PDF) |
| 179 | ERS statement on harmonised standards for lung cancer registration and lung cancer services in Europe | 8.7 | 14 | Citations (PDF) |
| 180 | Short Communication: Management of patients with extensive-stage small-cell lung cancer treated with radiotherapy: A survey of practice | 1.7 | 3 | Citations (PDF) |
| 181 | Residual Setup Errors Towards the Heart After Image Guidance Linked With Poorer Survival in Lung Cancer Patients: Do We Need Stricter IGRT Protocols? | 1.5 | 47 | Citations (PDF) |
| 182 | Practice-changing radiation therapy trials for the treatment of cancer: where are we 150 years after the birth of Marie Curie? | 5.5 | 112 | Citations (PDF) |
| 183 | LungTech: Stereotactic Body Radiotherapy (SBRT) of Inoperable Centrally Located Non-small Cell Lung Cancer (NSCLC) | 1.6 | 0 | Citations (PDF) |
| 184 | The use of volunteers to implement electronic patient reported outcomes in lung cancer outpatient clinics | 2.1 | 4 | Citations (PDF) |
| 185 | PV-0036 The effect of tumour laterality on survival for non-small cell lung cancer patients | 2.0 | 0 | Citations (PDF) |
| 186 | PV-0037: Correlation between coronary artery doses and survival in locally advanced lung cancer patients | 2.0 | 0 | Citations (PDF) |
| 187 | OC-0322: Residual setup errors after IGRT are linked to overall survival in lung and oesophageal cancers | 2.0 | 1 | Citations (PDF) |
| 188 | SP-0551: For the motion | 2.0 | 0 | Citations (PDF) |
| 189 | PO-0751: Radiomic feature changes in small cell lung cancer IGRT relate significantly to overall survival | 2.0 | 0 | Citations (PDF) |
| 190 | EP-1991: Tumour sphericity is an independent predictor for overall survival in non-small cell lung cancer | 2.0 | 0 | Citations (PDF) |
| 191 | EP-2063: An audit of adaptive radiotherapy in a large centre | 2.0 | 3 | Citations (PDF) |
| 192 | Magnetic Resonance Imaging–Guided Radiation Therapy: A Short Strengths, Weaknesses, Opportunities, and Threats Analysis | 1.5 | 102 | Citations (PDF) |
| 193 | Learning from every patient treated | 1.6 | 0 | Citations (PDF) |
| 194 | Study protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancer | 1.9 | 73 | Citations (PDF) |
| 195 | Immune Checkpoint Inhibitors in Lung Cancer – An Unheralded Opportunity? | 1.6 | 6 | Citations (PDF) |
| 196 | Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy: A secondary analysis of the Phase III CREST trial | 2.6 | 94 | Citations (PDF) |
| 197 | Developing and Validating a Survival Prediction Model for NSCLC Patients Through Distributed Learning Across 3 Countries | 1.5 | 126 | Citations (PDF) |
| 198 | Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial | 27.4 | 560 | Citations (PDF) |
| 199 | Scientific Advances in Thoracic Oncology 2016 | 2.1 | 50 | Citations (PDF) |
| 200 | Effect of accurate heart delineation on cardiac dose during the CONVERT trial | 2.4 | 13 | Citations (PDF) |
| 201 | Management of stage I and II nonsmall cell lung cancer | 8.7 | 72 | Citations (PDF) |
| 202 | Using the Malthus programme to predict the recruitment of patients to MR-linac research trials in prostate and lung cancer | 2.0 | 7 | Citations (PDF) |
| 203 | Posttreatment Lymphocytopenia, Integral Heart Dose, and Overall Survival in Lung Cancer Patients Treated With Radical Radiation Therapy | 1.5 | 1 | Citations (PDF) |
| 204 | Radiation dose to heart base linked with poorer survival in lung cancer patients | 4.9 | 204 | Citations (PDF) |
| 205 | OC-0141: Validation of dose-sensitive heart regions affecting survival in SABR lung cancer patients | 2.0 | 0 | Citations (PDF) |
| 206 | PV-0286: Quantifying registration uncertainties in image-based data mining | 2.0 | 0 | Citations (PDF) |
| 207 | EP-1228: UK NCRI CTRad consensus on drug and radiotherapy combination platform studies in NSCLC | 2.0 | 6 | Citations (PDF) |
| 208 | PO-0952: Integral heart dose and lymphocytopaenia in lung cancer patients treated with radical radiotherapy | 2.0 | 0 | Citations (PDF) |
| 209 | EP-1601: Do higher CT pixel values outside the GTV predict for poorer lung cancer survival? | 2.0 | 0 | Citations (PDF) |
| 210 | EP-1713: Feasibility of low dose 4D CBCT in patients with lung cancer | 2.0 | 0 | Citations (PDF) |
| 211 | A multi-centre dosimetry audit on advanced radiotherapy in lung as part of the Isotoxic IMRT study | 2.2 | 7 | Citations (PDF) |
| 212 | European Organization for Research and Treatment of Cancer (EORTC) recommendations for planning and delivery of high-dose, high precision radiotherapy for lung cancer | 2.0 | 220 | Citations (PDF) |
| 213 | The clinical utility of circulating tumour cells in patients with small cell lung cancer | 2.0 | 34 | Citations (PDF) |
| 214 | Magnetic resonance imaging in precision radiation therapy for lung cancer | 2.0 | 68 | Citations (PDF) |
| 215 | How do the QUARTZ trial results inform future research for patients with brain metastases from non-small cell lung cancer? | 1.2 | 0 | Citations (PDF) |
| 216 | The Challenges Faced in Developing Novel Drug Radiation Combinations in Non-small Cell Lung Cancer | 1.6 | 7 | Citations (PDF) |
| 217 | Protocol for the CONVERT trial—Concurrent ONce-daily VErsus twice-daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status | 1.9 | 40 | Citations (PDF) |
| 218 | Protocol for the isotoxic intensity modulated radiotherapy (IMRT) in stage III non-small cell lung cancer (NSCLC): a feasibility study | 1.9 | 26 | Citations (PDF) |
| 219 | Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial | 62.1 | 677 | Citations (PDF) |
| 220 | OC-0257: A Bayesian network model for acute dysphagia prediction in the clinic for NSCLC patients | 2.0 | 0 | Citations (PDF) |
| 221 | EP-1844: Feasibility of generating mid-position CT from 4DCT using commercial deformable registration systems | 2.0 | 2 | Citations (PDF) |
| 222 | OC-0140: Management of patients with extensive-stage small-cell lung cancer: A European survey of practice | 2.0 | 3 | Citations (PDF) |
| 223 | PO-0788: Predicted patient demand for MRI Linac | 2.0 | 0 | Citations (PDF) |
| 224 | The Current Role of Radiotherapy in the Treatment of Small Cell Lung Cancer | 1.6 | 15 | Citations (PDF) |
| 225 | SP-0617: IMRT for lung cancer: current status and futuredevelopments | 2.0 | 0 | Citations (PDF) |
| 226 | Protocol for PIT: a phase III trial of prophylactic irradiation of tracts in patients with malignant pleural mesothelioma following invasive chest wall intervention | 1.9 | 28 | Citations (PDF) |
| 227 | Brain Metastases from NSCLC: Radiation Therapy in the Era of Targeted Therapies | 2.1 | 79 | Citations (PDF) |
| 228 | Imaging biomarker roadmap for cancer studies | 70.7 | 986 | Citations (PDF) |
| 229 | PO-0656: Effect of accurate heart outlining on radiation dose to the heart - the CONVERT Trial experience | 2.0 | 0 | Citations (PDF) |
| 230 | PO-0658: Quality assurance programme for the isotoxic intensity modulated radiotherapy feasibility study | 2.0 | 0 | Citations (PDF) |
| 231 | SP-0203: Dose / fractionation / IMRT / Imaging | 2.0 | 0 | Citations (PDF) |
| 232 | PO-0985: How accurate is lung IMRT and VMAT delivery? A multicentre audit as part of the Isotoxic IMRT trial | 2.0 | 0 | Citations (PDF) |
| 233 | EP-1527: Early results from a clinical trial of visual feedback from dynamic optical surface sensing in lung cancer patients | 2.0 | 0 | Citations (PDF) |
| 234 | Discovery and Validation of Predictive Biomarkers of Survival for Non-small Cell Lung Cancer Patients Undergoing Radical Radiotherapy: Two Proteins With Predictive Value | 9.7 | 32 | Citations (PDF) |
| 235 | PO-0660: A survey of current lung radiotherapy treatment techniques used during the CONVERT Trial | 2.0 | 0 | Citations (PDF) |
| 236 | PO-1119 Suitability of lung margins following analysis of set up data within a multi-national lung trial | 2.0 | 0 | Citations (PDF) |
| 237 | LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective | 2.4 | 103 | Citations (PDF) |
| 238 | 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer | 9.9 | 369 | Citations (PDF) |
| 239 | Postoperative Radiotherapy for Pathologic N2 Non–Small-Cell Lung Cancer Treated With Adjuvant Chemotherapy: Need for Randomized Evidence | 16.9 | 16 | Citations (PDF) |
| 240 | PO-0663: Lung V5 does not predict for lung toxicity after fixed-beam intensity modulated radiotherapy (IMRT) for lung cancer | 2.0 | 0 | Citations (PDF) |
| 241 | Stereotactic body radiotherapy for central lung tumours:<i>Author reply</i> | 2.4 | 0 | Citations (PDF) |
| 242 | Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial | 62.1 | 570 | Citations (PDF) |
| 243 | Outcomes of Elderly Patients (≥70 Yo) with Advanced Non-Small Cell Lung Cancer (Nsclc): a Multi-Institutional Analysis | 9.9 | 0 | Citations (PDF) |
| 244 | Randomized Trial of Erlotinib Plus Whole-Brain Radiotherapy for NSCLC Patients With Multiple Brain Metastases | 4.6 | 110 | Citations (PDF) |
| 245 | 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease | 9.9 | 225 | Citations (PDF) |
| 246 | High-dose re-irradiation following radical radiotherapy for non-small-cell lung cancer | 27.4 | 96 | Citations (PDF) |
| 247 | Intensity-Modulated Radiotherapy for Lung Cancer: Current Status and Future Developments | 2.1 | 81 | Citations (PDF) |
| 248 | Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer | 9.9 | 266 | Citations (PDF) |
| 249 | How can we optimise concurrent chemoradiotherapy for inoperable stage III non-small cell lung cancer? | 2.6 | 35 | Citations (PDF) |
| 250 | New radiotherapy approaches in locally advanced non-small cell lung cancer | 4.9 | 48 | Citations (PDF) |
| 251 | Early reduction in tumour [18F]fluorothymidine (FLT) uptake in patients with non-small cell lung cancer (NSCLC) treated with radiotherapy alone | 5.5 | 41 | Citations (PDF) |
| 252 | 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up | 9.9 | 477 | Citations (PDF) |
| 253 | Investigation of a Patient Reported Outcome tool to assess radiotherapy-related toxicity prospectively in patients with lung cancer | 2.0 | 28 | Citations (PDF) |
| 254 | Cancers bronchiques non à petites cellules localement avancés : quelle radiothérapie en 2014 ? | 0.0 | 0 | Citations (PDF) |
| 255 | Traditional Phase 1 and 2 Studies in Thoracic Radiation Oncology Should Be Abandoned | 1.5 | 13 | Citations (PDF) |
| 256 | Is pre-trial quality assurance necessary? Experiences of the CONVERT Phase III randomized trial for good performance status patients with limited-stage small-cell lung cancer | 2.4 | 18 | Citations (PDF) |
| 257 | An Isotoxic Planning Comparison Study for Stage II–III Non-small Cell Lung Cancer: Is Intensity-modulated Radiotherapy the Answer? | 1.6 | 15 | Citations (PDF) |
| 258 | Stereotactic body radiotherapy (SBRT) in central non-small cell lung cancer (NSCLC): Solid evidence or “no-go”? | 2.0 | 16 | Citations (PDF) |
| 259 | Radical treatment of non-small cell lung cancer during the last 5 years | 4.9 | 55 | Citations (PDF) |
| 260 | Is stereotactic ablative radiotherapy equivalent to sublobar resection in high-risk surgical patients with Stage I non-small-cell lung cancer?: Table 1: | 1.4 | 26 | Citations (PDF) |
| 261 | Improving care for patients with lung cancer in the UK | 5.6 | 10 | Citations (PDF) |
| 262 | PO-0724: Comparison of volume delineation on simultaneous and standard cone beam CT images during arc radiotherapy (SCART) | 2.0 | 0 | Citations (PDF) |
| 263 | EP-1087: The clinical usefulness of simultaneous cone beam CT scans captured during prostate radiotherapy | 2.0 | 0 | Citations (PDF) |
| 264 | Modern Management of Small-Cell Lung CancerDrugs, 2012, 67, 2135-2152 | 11.4 | 33 | Citations (PDF) |
| 265 | Efficacy of Positron Emission Tomography Staging for Small-Cell Lung Cancer: A Systematic Review and Cost Analysis in the Australian Setting | 2.1 | 0 | Citations (PDF) |
| 266 | Management of Small Cell Lung Cancer | 11.4 | 67 | Citations (PDF) |
| 267 | Concurrent Chemoradiotherapy for Locally Advanced, Unresectable Non-small Cell Lung Cancer: A UK Survey of Current Practice | 1.6 | 7 | Citations (PDF) |
| 268 | Targeted agents in non-small cell lung cancer (NSCLC): Clinical developments and rationale for the combination with thoracic radiotherapy | 9.5 | 78 | Citations (PDF) |
| 269 | SP-0407 CURRENT PRACTICE AND MOVING POINTS: LUNG | 2.0 | 0 | Citations (PDF) |
| 270 | Omitting elective nodal irradiation during thoracic irradiation in limited-stage small cell lung cancer – Evidence from a phase II trial | 2.6 | 40 | Citations (PDF) |
| 271 | Radical radiotherapy with or without gemcitabine in patients with early stage medically inoperable non-small cell lung cancer | 2.6 | 8 | Citations (PDF) |
| 272 | Long-term Toxicity Report From a Phase II Study of Accelerated Twice-Daily (BD) versus High Dose Once-Daily (OD) Thoracic Radiotherapy (RT) With Concurrent Chemotherapy for Limited-Stage Small Cell Lung Cancer (LS-SCLC) | 1.5 | 3 | Citations (PDF) |
| 273 | Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer group | 2.6 | 5 | Citations (PDF) |
| 274 | Use of G-CSF during concurrent chemotherapy and thoracic radiotherapy in patients with limited-stage small-cell lung cancer safety data from a phase II trial | 2.6 | 17 | Citations (PDF) |
| 275 | The role of positron emission tomography in management of small cell lung cancer | 2.6 | 41 | Citations (PDF) |
| 276 | Treatment of limited small cell lung cancer: an old or new challenge? | 2.1 | 9 | Citations (PDF) |
| 277 | Reactive Plan Adaptation for Lung Radiotherapy Based on Cone Beam CT —The Christie Experience | 1.6 | 1 | Citations (PDF) |
| 278 | An Examination of the Recruitment of Patients to NCRN (National Cancer Research Network) Lung Cancer Radiotherapy Trials at The Christie | 1.6 | 0 | Citations (PDF) |
| 279 | CONVERT – the Challenges of Opening a Multi-centre Radiotherapy Trial in the UK | 1.6 | 0 | Citations (PDF) |
| 280 | Survival of Patients with Non-small Cell Lung Cancer and Brain Metastases | 1.6 | 3 | Citations (PDF) |
| 281 | Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01) | 9.9 | 181 | Citations (PDF) |
| 282 | Optimising Recruitment Rates to Radiotherapy Clinical Trials for Patients with Non-small Cell Lung Cancer and Brain Metastases | 1.6 | 3 | Citations (PDF) |
| 283 | Guidelines on the radical management of patients with lung cancer | 5.6 | 431 | Citations (PDF) |
| 284 | European Organisation for Research and Treatment of Cancer Recommendations for Planning and Delivery of High-Dose, High-Precision Radiotherapy for Lung Cancer | 16.9 | 294 | Citations (PDF) |
| 285 | Radiotherapy for lung cancer in the elderly | 2.6 | 34 | Citations (PDF) |
| 286 | Meeting report: 2nd meeting of the European Thoracic Oncology Platform (ETOP) | 2.6 | 0 | Citations (PDF) |
| 287 | Lung cancer after treatment for breast cancer | 27.4 | 34 | Citations (PDF) |
| 288 | The European Respiratory Society and European Society of Thoracic Surgeons clinical guidelines for evaluating fitness for radical treatment (surgery and chemoradiotherapy) in patients with lung cancer | 1.4 | 127 | Citations (PDF) |
| 289 | Lung function evaluation before surgery in lung cancer patients: how are recent advances put into practice? A survey among members of the European Society of Thoracic Surgeons (ESTS) and of the Thoracic Oncology Section of the European Respiratory Society (ERS) | 1.4 | 38 | Citations (PDF) |
| 290 | Prophylactic Cranial Irradiation in Extensive Disease Small-Cell Lung Cancer: Short-Term Health-Related Quality of Life and Patient Reported Symptoms—Results of an International Phase III Randomized Controlled Trial by the EORTC Radiation Oncology and Lung Cancer Groups | 16.9 | 255 | Citations (PDF) |
| 291 | Radiotherapy in Extensive-disease Small Cell Lung Cancer. A Survey of Current UK Practice | 1.6 | 5 | Citations (PDF) |
| 292 | Response on Behalf of the UK Stereotactic Body Radiotherapy Consortium to Brock et al. Clin Oncol (R Coll Radiol) 2008;20(9):666–676 | 1.6 | 1 | Citations (PDF) |
| 293 | Radiotherapy for small-cell lung cancer—Where are we heading? | 2.6 | 43 | Citations (PDF) |
| 294 | Prophylactic radiotherapy to intervention sites in mesothelioma: A systematic review and survey of UK practice | 2.6 | 60 | Citations (PDF) |
| 295 | Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial | 27.4 | 344 | Citations (PDF) |
| 296 | Prise en charge du cancer bronchique à petites cellules (CPC) (localisé et étendu) | 0.0 | 0 | Citations (PDF) |
| 297 | Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer | 5.5 | 49 | Citations (PDF) |
| 298 | Management of Unresectable Stage III Non–Small-Cell Lung Cancer with Combined-Modality Therapy: A Review of the Current Literature and Recommendations for Treatment | 2.8 | 24 | Citations (PDF) |
| 299 | Small Cell Lung Cancer (SCLC); any progress? | 0.5 | 0 | Citations (PDF) |
| 300 | Prophylactic Cranial Irradiation in Extensive Small-Cell Lung Cancer | 34.5 | 1,118 | Citations (PDF) |
| 301 | Optimal Planning and Delivery of Radiotherapy for Oesophago-gastric Junction (OGJ) Cancers | 1.6 | 0 | Citations (PDF) |
| 302 | Re: Small Cell Lung Cancer Treated in Southeast Wales, Lester et al., Clin Oncol 2006;18:378–382 | 1.6 | 0 | Citations (PDF) |
| 303 | Thoracic Radiotherapy for Limited-stage Small-cell Lung Cancer: Controversies and Future developments | 1.6 | 23 | Citations (PDF) |
| 304 | Management of small-cell lung cancer | 9.9 | 38 | Citations (PDF) |
| 305 | Platinum-based chemotherapy with thoracic radiotherapy in stage III good performance status non-small cell lung cancer patients | 0.5 | 0 | Citations (PDF) |
| 306 | Thoracic Radiation Therapy for Limited-Stage Small-Cell Lung Cancer: Unanswered Questions | 2.8 | 22 | Citations (PDF) |
| 307 | O-90 Randomised phase III trial of docetaxel/carboplatin vs. MIC/MVP chemotherapy in inoperable advanced non-small cell lung cancer (NSCLC) — A British thoracic oncology group (BTOG) trial | 2.6 | 1 | Citations (PDF) |
| 308 | Effect of age, period of diagnosis and birth cohort on large bowel cancer incidence in a well-defined French population, 1976–1995 | 2.0 | 25 | Citations (PDF) |
| 309 | Chemotherapy for colon cancer in a well-defined French population: is it under- or over-prescribed? | 3.7 | 38 | Citations (PDF) |
| 310 | Changes in the practice of adjuvant radiotherapy in resectable rectal cancer within a French well-defined population | 2.0 | 18 | Citations (PDF) |
| 311 | The advanced radiotherapy network (ART-NET) UK lung stereotactic ablative radiotherapy survey: national provision and a focus on image guidance | 2.4 | 11 | Citations (PDF) |
| 312 | Examining the Effectiveness of Electronic Patient-Reported Outcomes in People With Cancer: Systematic Review and Meta-Analysis | 7.7 | 34 | Citations (PDF) |
| 313 | Survival and Radiotherapy-Related Adverse Events in Patients Receiving Radiotherapy and Concurrent Metformin: A Systematic Review and Meta-Analysis of Randomised Controlled Trials and Cohort Studies | 4.2 | 2 | Citations (PDF) |
| 314 | Prise en charge des cancers bronchiques à petites cellules de stade localisé : actualisation | 0.0 | 0 | Citations (PDF) |
| 315 | Unresectable stage III non-small-cell lung cancer: state of the art and challenges | 70.7 | 9 | Citations (PDF) |
| 316 | Definition of resectable stage III non-small cell lung cancer (NSCLC) for inclusion in clinical trials: A clinical case review by a pan-European multidisciplinary expert panel led by the EORTC Lung Cancer Group | 2.6 | 8 | Citations (PDF) |
| 317 | Impact of statin use on survival and adverse events in patients with cancer receiving radiotherapy: a systematic review and meta-analysis | 2.9 | 0 | Citations (PDF) |
| 318 | The concept of virtual clinical trials: A game changer in radiation oncology research? | 2.0 | 0 | Citations (PDF) |
| 319 | Inequalities in the utilisation of curative-intent treatments for early-stage non-small cell lung cancer across urban and rural areas: A population-based study in England | 1.4 | 1 | Citations (PDF) |
| 320 | European Respiratory Society and European Society of Thoracic Surgeons clinical practice guideline on fitness for curative intent treatment of lung cancer | 1.4 | 1 | Citations (PDF) |
| 321 | Radiotherapy outcomes in patients with interstitial lung disease and interstitial lung abnormalities: Adverse events and survival from a UK tertiary centre | 2.6 | 1 | Citations (PDF) |
| 322 | Corrigendum to “Radiotherapy outcomes in patients with interstitial lung disease and interstitial lung abnormalities: Adverse events and survival from a UK tertiary centre” [Lung Cancer 211 (2026) 108873 | 2.6 | 0 | Citations (PDF) |
| 323 | 202 Localised non-small cell lung cancer: patient characteristics and radical radiotherapy outcomes according to KRAS mutation status | 2.6 | 0 | Citations (PDF) |
| 324 | 260 A retrospective review of the use of PCI and the neurological outcomes for patients receiving platinum, etoposide and atezolizumab for treatment of extensive-stage small cell lung cancer (ES-SCLC) at The Clatterbridge Cancer Centre (CCC) and The Christie | 2.6 | 0 | Citations (PDF) |
| 325 | Evaluating the prognostic impact of multiple 18FDG-PET imaging parameters in small-cell lung cancer: Insights from the long-term analysis of the CONVERT trial | 5.5 | 0 | Citations (PDF) |
| 326 | The Optimization of Radiotherapy in Lung Cancer Treatment: 20 Years of Progress | 2.1 | 0 | Citations (PDF) |
| 327 | Navigating controversies in stage III NSCLC: a multidisciplinary case discussion on evolving treatment paradigms | 2.6 | 0 | Citations (PDF) |
